“The pharmaceutical industry will become a new investment hot spot for the market in the future†was recently held by Ernst & Young’s “Milestone's 08 China High-growth CEO Forumâ€, and some international investment bankers agreed. At the same time, Ernst & Young’s research report also pointed out that due to the expansion of China’s health care plan and the increase in population affluence, the demand for drugs is increasing. In the next few years, China will become one of the most important growth markets.
It is understood that many international multinational pharmaceutical companies have accelerated their penetration of the Chinese market. There are mainly three business models they adopt: First, increase investment in R&D in China; second, expand sales and market operations in China; Local companies establish partnerships to sell products in China. “As the international multinational pharmaceutical companies accelerate their expansion in China, the competition in the domestic pharmaceutical industry will also become increasingly fierce.†Carolyn Buck-Luce, head of the global pharmaceutical industry at Ernst & Young, told reporters that under such market conditions, the domestic pharmaceutical industry should Consider how to make your own changes.
And, according to Glen Giovannetti, a partner in the global biotechnology industry at Ernst & Young, Chinese pharmaceutical companies can consider “going outâ€. He believes that the current value of biotechnology companies has shrunk dramatically, which is also an opportunity for Chinese pharmaceutical companies to go overseas for mergers and acquisitions. However, he also pointed out that before domestic pharmaceutical companies “go out,†they must first train their own internal strength.
In fact, China's pharmaceutical companies have already tried to go abroad to go overseas for mergers and acquisitions and achieved gratifying results.
On January 31st this year, WuXi PharmaTech, a leading company in China's pharmaceutical R&D outsourcing industry, completed the acquisition of App Tec Laboratories, an American biopharmaceutical and medical device R&D outsourcing service provider, for approximately US$163 million; March 12 , China's largest monitor manufacturer, Shenzhen Mindray announced its first acquisition decision after its overseas listing - US$202 million acquisition of the United States Datascope's life information monitoring business, after the completion of the acquisition, Mindray will become the world's third largest monitor industry Big manufacturers.
On April 9, Wanquan Science & Technology Pharmaceuticals, a Hong Kong-listed company, officially announced that it has acquired 39% of the issued share capital of Commonwealth Biotechnologies Inc. (CBI), a NASDAQ-listed company, for US$311.75 million (approximately HK$24.316 million) in cash. , became the group's largest shareholder.
At the same time as “testing water†foreign mergers and acquisitions, domestic capital mergers and acquisitions are also raging. Data show that in 2007 there were 43 mergers and acquisitions in the national pharmaceutical industry, involving a total amount of 3.4 billion yuan. In 2008, mergers and acquisitions in the pharmaceutical industry became more frequent and active. The main trend is the reintegration of resources, as well as the scale and intensification of operations.
"China's pharmaceutical industry is in a period of rapid growth," said Li Yongguang, partner in the pharmaceutical industry in Anyongdong District. After accelerating domestic mergers and acquisitions integration, there will be more and more companies going out. He believes that China is currently considered to be one of the fastest-growing pharmaceutical markets. Global pharmaceutical companies expand their operations in the Chinese market, which shows that China’s growing purchasing power and coverage as well as ongoing medical systems are all domestic pharmaceutical companies. Brought an important opportunity for development.
Powder Metallurgy
Powder metallurgy is an industrial technology that produces metal powder or uses metal powder (or a mixture of metal powder and non-metal powder) as a raw material, after forming and sintering, to produce metal materials, composite materials and various types of products. Powder metallurgy technology has been widely used in the fields of transportation, machinery, electronics, aerospace, weapons, biology, new energy, information and nuclear industry, and has become one of the most dynamic branches of new materials science. Powder metallurgy technology has a series of advantages such as significant energy saving, material saving, excellent performance, high product precision and good stability, which is very suitable for mass production. In addition, some materials and complex parts that cannot be prepared by traditional casting methods and mechanical processing methods can also be manufactured by powder metallurgy technology, which has attracted the attention of the industry.
Powder Metallurgy,Sintering In Powder Metallurgy,Powder Metallurgy Process,Powder Metallurgy Parts
Ningbo Huilexin Technology Co.LTD , https://www.oemshockabsorbers.com